Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sreenath V Sharma

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Oncotarget|June 18, 2011
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translationErik A Nelson, Sreenath V Sharma, Jeffrey Settleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
"Oncogenic shock": explaining oncogene addiction through differential signal attenuationSreenath V Sharma, Michael A Fischbach, Daniel A Haber, et al.
Analytical Biochemistry|December 24, 2008
Drug-target identification from total cellular lysate by drug-induced conformational changesYoichi Nishiya, Kenji Shibata, Seiji Saito, et al.
Chemistry & Biology|May 29, 2003
Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15AChitose Oneyama, Tsutomu Agatsuma, Yutaka Kanda, et al.
Biochemical Pharmacology|December 31, 2003
A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assayAkira Asai, Tetsuya Tsujita, Sreenath V Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentTan Min Chin, Margaret P Quinlan, Anurag Singh, et al.
Cancer Cell|November 14, 2006
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenesSreenath V Sharma, Patrycja Gajowniczek, Inna P Way, et al.
Chemistry & Biology|March 27, 2010
A structure-guided approach to creating covalent FGFR inhibitorsWenjun Zhou, Wooyoung Hur, Ultan McDermott, et al.
Cancer Research|October 23, 2015
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung CancerAlexandra B Lantermann, Dongshu Chen, Kaitlin McCutcheon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastropheFabrizio Galimberti, Sarah L Thompson, Xi Liu, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Oncotarget|June 18, 2011
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translationErik A Nelson, Sreenath V Sharma, Jeffrey Settleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
"Oncogenic shock": explaining oncogene addiction through differential signal attenuationSreenath V Sharma, Michael A Fischbach, Daniel A Haber, et al.
Analytical Biochemistry|December 24, 2008
Drug-target identification from total cellular lysate by drug-induced conformational changesYoichi Nishiya, Kenji Shibata, Seiji Saito, et al.
Chemistry & Biology|May 29, 2003
Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15AChitose Oneyama, Tsutomu Agatsuma, Yutaka Kanda, et al.
Biochemical Pharmacology|December 31, 2003
A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assayAkira Asai, Tetsuya Tsujita, Sreenath V Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentTan Min Chin, Margaret P Quinlan, Anurag Singh, et al.
Cancer Cell|November 14, 2006
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenesSreenath V Sharma, Patrycja Gajowniczek, Inna P Way, et al.
Chemistry & Biology|March 27, 2010
A structure-guided approach to creating covalent FGFR inhibitorsWenjun Zhou, Wooyoung Hur, Ultan McDermott, et al.
Cancer Research|October 23, 2015
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung CancerAlexandra B Lantermann, Dongshu Chen, Kaitlin McCutcheon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastropheFabrizio Galimberti, Sarah L Thompson, Xi Liu, et al.
Pageof 3